Abstract: Disclosed is scattered ray-shielding underwear for radiation therapy. The scattered ray-shielding underwear for radiation therapy, according to an embodiment of the present disclosure, comprises an outer underwear formed of a first shielding material and an inner underwear formed of a second shielding material, wherein the first shielding material has a greater atomic number than the second shielding material, and thus, during radiation therapy, the outer underwear can shield scattered rays generated by high-energy radiation, and the inner underwear can shield braking radiation, and exposure of a patient to scattered rays and braking radiation can be almost completely blocked.

Abstract: A brassiere for radiation therapy is disclosed. The brassiere for radiation therapy according to an embodiment of the present disclosure includes a pair of cups configured to cover breasts of a patient; a coupling member positioned between the pair of cups and configured to couple the pair of cups to each other; back bands configured to be in close contact with a back of the patient; and side compression bands, the side compression bands having one ends coupled to the pair of cups at the coupling member, respectively, and the other ends detachably coupled to the back bands, respectively, wherein positions of the breasts of the patient are changed by adjusting positions on the back bands to which the other ends of side compression bands are coupled.

Abstract: Disclosed are a method, a composition, a microarray, an antibody and a kit for diagnosis and prognosis of cancer, based on detection of deletion of the exon 3 region of G-CSF gene or levels of a mutated G-CSF protein having a deletion of an amino acid sequence corresponding to the exon 3 region, wherein the deletion of the exon 3 region of the G-CSF gene is used as a cancer biomarker.

Abstract: Disclosed are a method, a composition, a microarray, an antibody and a kit for diagnosis and prognosis of cancer, based on detection of deletion of the exon 3 region of G-CSF gene or levels of a mutated G-CSF protein having a deletion of an amino acid sequence corresponding to the exon 3 region, wherein the deletion of the exon 3 region of the G-CSF gene is used as a cancer biomarker.

Abstract: Disclosed are a method, a composition, a microarray, an antibody and a kit for diagnosis and prognosis of cancer, based on detection of deletion of the exon 3 region of G-CSF gene or levels of a mutated G-CSF protein having a deletion of an amino acid sequence corresponding to the exon 3 region, wherein the deletion of the exon 3 region of the G-CSF gene is used as a cancer biomarker.

Abstract: Disclosed are a method, a composition, a microarray, an antibody and a kit for diagnosis and prognosis of cancer, based on detection of deletion of the exon 3 region of G-CSF gene or levels of a mutated G-CSF protein having a deletion of an amino acid sequence corresponding to the exon 3 region, wherein the deletion of the exon 3 region of the G-CSF gene is used as a cancer biomarker.

Abstract: The present invention relates to a pharmaceutical composition for the treatment of wounds containing blood plasma or serum and a method for treating wounds effectively by applying said composition to the wound site to normalize the tissue-environment around the site.

Abstract: Disclosed are a method, a composition, a microarray, an antibody and a kit for diagnosis and prognosis of cancer, based on detection of deletion of the exon 3 region of G-CSF gene or levels of a mutated G-CSF protein having a deletion of an amino acid sequence corresponding to the exon 3 region, wherein the deletion of the exon 3 region of the G-CSF gene is used as a cancer biomarker.

Abstract: The present invention relates to nucleic acid probes specific to Staphylococcus aureus, which is useful for detecting and identifying S. aureus in a biological sample. More particularly, the present invention relates to a DNA chip for detecting and identifying S. aureus, on which nucleic acid probes derived from 23 S rRNA gene of S. aureus are immobilized. The application of the DNA chips according to the present invention allows time-saving and accurate diagnosis of bacterial infection compared with the conventional bacterial culture methods.

Abstract: The present invention relates to nucleic acid probes specific to E. coli, which is useful for detecting and identifying E. coli in a biological sample. More particularly, the present invention relates to a DNA chip for detecting and identifying E. coli, on which nucleic acid probes derived from 23 S rRNA gene of E. coli are immobilized. The application of the DNA chip according to the present invention allows time-saving and accurate diagnosis of bacterial infection compared with the conventional of bacterial culture methods. In addition, it is not affected by antibiotics addition in clinical practice, thus leading to more accurate diagnosis.

Abstract: The present invention relates to oligonucleotides for diagnosis of corneal dystrophy. More particularly, the present invention relates to oligonucleotides for detecting mutation of BIGH3 gene for diagnosis or corneal dystrophy including Avellino corneal dystrophy, which must be precisely diagnosed before vision correction surgery, and a DNA chip for diagnosis of corneal dystrophy, which has the oligonucleotides fixed thereon. According to the present invention, conventional microscopic diagnosis of corneal dystrophy can be replaced with a precise genetic method, which prevents a patient with corneal dystrophy from losing eyesight by eyesight correction surgery after erroneous diagnosis.

Abstract: The present invention relates to a diagnostic cancer marker using variation of a granulocyte colony stimulating factor (G-CSF) gene and a method for preparing the same, and more specifically, relates to a method for diagnosing cancer and/or assessing the state of cancer progression using an oligonucleotide having the 3?-terminal end of exon 2 region linked to the 5?-terminal end of exon 4 region of a G-CSF gene as a diagnostic cancer marker. According to the present invention, cancer can be quickly and exactly diagnosed using variation in a G-CSF gene expression.

Abstract: The present invention relates to a pharmaceutical composition for the treatment of nerve damage, and more particularly to a pharmaceutical composition for the treatment of nerve damage, which contains blood plasma or serum as an active ingredient. The inventive composition regenerates nerve cells after spinal nerve damage and provides complete structural continuity in the spinal nerve lesion sites. Thus, the composition is useful for the treatment of nerve damage.

Abstract: The present invention relates to a composition for treating alopecia or promoting hair growth, which contains the blood plasma or serum as an active ingredient. The inventive composition is effective in hair growth, hair growth promotion and hair loss prevention.

Abstract: The present invention relates to methods and compositions for inhibiting scar formation on wound region. In certain embodiments, the methods include administering an alkalinization agent in combination with hyaluronic acid to a wound site to reduce the formation of scars at the wound site. Suitable alkalization agents include sodium bicarbonate, sodium hydroxide and potassium hydroxide.

Abstract: The present invention relates to an agent for reducing scar formation, which inhibits the scar formation by injecting sodium bicarbonate to the dermis tissue of the wound with a syringe to directly control pH of the wound site, namely, by alkalinizing the wound to inactivate TGF-?. According to the present invention, the agent for reducing scar formation by controlling the wound healing process can be clinically and immediately applied to the treatment of tylosis scar and keloid, etc., and is effective to the treatment of intractable fibrosis diseases. Also, the invention can be widely applied in many ways as an easy tool which can control the action of TGF-? in a living organism.

Abstract: Disclosed are a method, a composition, a microarray, an antibody and a kit for diagnosis and prognosis of cancer, based on detection of deletion of the exon 3 region of G-CSF gene or levels of a mutated G-CSF protein having a deletion of an amino acid sequence corresponding to the exon 3 region, wherein the deletion of the exon 3 region of the G-CSF gene is used as a cancer biomarker.

Abstract: The present invention relates to an agent for reducing scar formation, which inhibits the scar formation by injecting sodium bicarbonate to the dermis tissue of the wound with a syringe to directly control pH of the wound site, namely, by alkalinizing the wound to inactivate TGF-&bgr;. According to the present invention, the agent for reducing scar formation by controlling the wound healing process can be clinically and immediately applied to the treatment of tylosis scar and keloid, etc., and is effective to the treatment of intractable fibrosis diseases. Also, the invention can be widely applied in many ways as an easy tool which can control the action of TGF-&bgr; in a living organism.